ACE-031 vs Myostatin Inhibitor
A side-by-side research comparison of ACE-031 and Myostatin Inhibitor across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | ACE-031 | Myostatin Inhibitor |
|---|---|---|
| Full name | ACE-031 (Soluble ActRIIB-Fc Fusion) | Myostatin Inhibitor Peptides (Anti-GDF-8) |
| Category | Muscle Growth | Muscle Growth |
| Status | Investigational | Research compound |
| Mechanism | Decoy receptor sequestering TGF-B ligands (myostatin, activin, GDF-11) in bloodstream, preventing cell-surface ActRIIB binding and removing multiple anabolic brakes. | Propeptide mimics bind mature myostatin; peptide aptamers block ActRIIB; small antagonists compete for receptor. All prevent myostatin-mediated suppression of muscle growth. |
| Molecular weight | ~90,000 Da | 2,000-15,000 Da (varies) |
| Half-life | 10-14 days | 4-48 hours (design-dependent) |
| Bioavailability | High (SubQ) | Variable (SubQ) |
| Typical dose | 0.3-3 mg/kg | 50-500 mcg |
| Frequency | Every 2-4 weeks | 3-7x per week |
| Route | Subcutaneous | Subcutaneous |
ACE-031 reported benefits
- Multi-ligand pathway inhibition
- Lean mass increase
- Bone density increase
- Infrequent dosing
- Functional strength improvement
Myostatin Inhibitor reported benefits
- Muscle growth promotion
- Strength increase
- Myostatin blockade
- Muscle wasting treatment potential
- Metabolic improvement
Related comparisons
Research and educational reference only. Not medical advice.